Evidence map›Paper›PMID 37507666›Full record

ArticleBMC infectious diseases2023

Multicenter study of the natural history and therapeutic responses of patients with chikungunya, focusing on acute and chronic musculoskeletal manifestations - a study protocol from the clinical and applied research in Chikungunya (REPLICK network).

Giselle da Silva Duarte, Alexandra D Jones, Luciano Pamplona de Goes Cavalcanti, Moacyr Jesus Barreto de Melo Rêgo, Guilherme S Ribeiro, Rosemary J Boyton, Dhelio Batista Pereira, Julio Henrique Rosa Croda, Fabio Trindade Maranhão Costa, Angela Pinto Duarte and 16 more

Abstract read
In one paragraph

Article in BMC infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Giselle da Silva DuarteLaboratório de Pesquisa Clínica Em Doenças Febris Agudas, Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil.
Alexandra D JonesUniversity of California, Berkeley, USA.
Luciano Pamplona de Goes CavalcantiUniversidade Federal Do Ceará, Fortaleza, Brazil.
Moacyr Jesus Barreto de Melo RêgoDepartamento de Bioquímica, Universidade Federal de Pernambuco, Recife, Brazil.
Guilherme S RibeiroInstituto Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, Brazil.
Rosemary J BoytonImperial College of London, London, UK.
Dhelio Batista PereiraCentro de Pesquisa Em Medicina Tropical de Rondônia, Porto Velho, Brazil.
Julio Henrique Rosa CrodaFundação Oswaldo Cruz, Mato Grosso Do Sul, Campo Grande, Brazil.
Fabio Trindade Maranhão CostaUniversidade Estadual de Campinas, Campinas, Brazil.
Angela Pinto DuarteHospital das Clínicas, Universidade Federal de Pernambuco, Recife, Brazil.
Marcia Edilaine Lopes ConsolaroDepartamento de Análises Clínicas E Biomedicina, Universidade Estadual de Maringá, Maringá, Brazil.
Rodrigo Guerino StabeliPlataforma de Medicina Translacional, Fundação Oswaldo Cruz, São Paulo, Brazil.
Fábio Juliano NegrãoUniversidade Federal da Grande Dourados, Dourados, Brazil.
Jose Luiz Proenca-ModenaUniversidade Estadual de Campinas, Campinas, Brazil.
Juan Miguel Villalobos-SalcedoFundação Oswaldo Cruz, São Paulo, Brazil.
Geraldo da Rocha Castelar PinheiroUniversidade Estadual Do Rio de Janeiro, Rio de Janeiro, Brazil.
Amanda Pinheiro de Barros AlbuquerqueDepartamento de Bioquímica, Universidade Federal de Pernambuco, Recife, Brazil.
Francisca Kalline de Almeida BarretoUniversidade Federal Do Ceará, Fortaleza, Brazil.
Jose MoreiraLaboratório de Pesquisa Clínica Em Doenças Febris Agudas, Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil.
Idalina Cristina FerrariUniversidade Federal da Grande Dourados, Dourados, Brazil.
Patricia Martinez ÉvoraPlataforma de Medicina Translacional, Fundação Oswaldo Cruz, São Paulo, Brazil.
Vânia Ramos Sela da SilvaDepartamento de Análises Clínicas E Biomedicina, Universidade Estadual de Maringá, Maringá, Brazil.
Marcus Vinicius Guimarães LacerdaFundação de Medicina Tropical Dr Heitor Vieira Dourado, Manaus, Brazil.
Daniel M AltmannImperial College of London, London, UK.
REPLICK network
André M SiqueiraLaboratório de Pesquisa Clínica Em Doenças Febris Agudas, Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil. andre.siqueira@ini.fiocruz.br.

Funding

Medical Research Council MR/S019553/1Medical Research Council MR/V036939/1
6 · The paper itself

Abstract

backgroundChikungunya is associated with high morbidity and the natural history of symptomatic infection has been divided into three phases (acute, post-acute, and chronic) according to the duration of musculoskeletal symptoms. Although this classification has been designed to help guide therapeutic decisions, it does not encompass the complexity of the clinical expression of the disease and does not assist in the evaluation of the prognosis of severity nor chronic disease. Thus, the current challenge is to identify and diagnose musculoskeletal disorders and to provide the optimal treatment in order to prevent perpetuation or progression to a potentially destructive disease course.

methodsThe study is the first product of the Clinical and Applied Research Network in Chikungunya (REPLICK). This is a prospective, outpatient department-based, multicenter cohort study in Brazil. Four work packages were defined: i. Clinical research; ii) Translational Science - comprising immunology and virology streams; iii) Epidemiology and Economics; iv) Therapeutic Response and clinical trials design. Scheduled appointments on days 21 (D21) ± 7 after enrollment, D90 ± 15, D120 ± 30, D180 ± 30; D360 ± 30; D720 ± 60, and D1080 ± 60 days. On these visits a panel of blood tests are collected in addition to the clinical report forms to obtain data on socio-demographic, medical history, physical examination and questionnaires devoted to the evaluation of musculoskeletal manifestations and overall health are performed. Participants are asked to consent for their specimens to be maintained in a biobank. Aliquots of blood, serum, saliva, PAXgene, and when clinically indicated to be examined, synovial fluid, are stored at -80° C. The study protocol was submitted and approved to the National IRB and local IRB at each study site. DISCUSSION: Standardized and harmonized patient cohorts are needed to provide better estimates of chronic arthralgia development, the clinical spectra of acute and chronic disease and investigation of associated risk factors. This study is the largest evaluation of the long-term sequelae of individuals infected with CHIKV in the Brazilian population focusing on musculoskeletal manifestations, mental health, quality of life, and chronic pain. This information will both define disease burden and costs associated with CHIKV infection, and better inform therapeutic guidelines.

Indexed as

Chikungunya FeverChronic DiseaseCohort StudiesHumansMulticenter Studies as TopicProspective StudiesQuality of LifeBrazilChikungunyaCohortRheumatic manifestations

Identifiers

PMID37507666
PMCPMC10386654

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.